Drug Trial Radar · NCT06922643
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Mar 1, 2011
Primary completion
Jan 21, 2013
Study completion Mar 1, 2013
Sponsor
- Lead sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock CompanyIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital. The study aims to provide affordable treatment options while evaluating the virological response and side effects associated with the therapy
Conditions
- Chronic Hepatitis C
Interventions
Peginterferon Alfa-2ADrug
180 mcg, subcutaneous injection, once weekly
Ribavirin Oral ProductDrug
15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virological Response (SVR)Time frame: 24 weeks post-treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.